(Q38007180)

26 August 2017

title

Mediators of chronic inflammation in polycystic ovarian syndrome (English)

1 reference

26 August 2017

0 references

E Deligeoroglou

1

1 reference

26 August 2017

N Vrachnis

2

1 reference

26 August 2017

N Athanasopoulos

3

1 reference

26 August 2017

Z Iliodromiti

4

1 reference

26 August 2017

S Sifakis

5

1 reference

26 August 2017

S Iliodromiti

6

1 reference

26 August 2017

C Siristatidis

7

1 reference

26 August 2017

G Creatsas

8

1 reference

26 August 2017

publication date

4 May 2012

1 reference

Gynecological Endocrinology

26 August 2017

published in

1 reference

26 August 2017

volume

28

1 reference

26 August 2017

issue

12

1 reference

26 August 2017

page(s)

974-978

1 reference

Evaluation and management of adolescent amenorrhea.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

The role of genes in the polycystic ovary syndrome: predisposition and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deteriora

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

The promoter -1031(T/C) polymorphism in tumor necrosis factor-alpha associated with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Lack of association between interleukin-1a gene (IL-1a) C (-889) T variant and polycystic ovary syndrome in Chinese women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Interleukin 1 beta (IL-1β) promoter C [-511] T polymorphism but not C [+3953] T polymorphism is associated with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09513590.2012.683082

10.3109/09513590.2012.683082

21 January 2018

Identifiers

DOI

1 reference

release_33nqau3dpbh73fewxut52q7evq

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/33nqau3dpbh73fewxut52q7evq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference